Cargando…
Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events
BACKGROUND: Comorbidities including ischemic heart disease (IHD) worsen outcomes after SARS‐CoV‐2 infections. High lipoprotein(a) [Lp(a)] concentrations are a strong risk factor for IHD and possibly for thromboembolic events. We therefore evaluated whether SARS‐CoV‐2 infections modify the risk of hi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242884/ https://www.ncbi.nlm.nih.gov/pubmed/34096654 http://dx.doi.org/10.1111/joim.13338 |
_version_ | 1783715662140538880 |
---|---|
author | Di Maio, Silvia Lamina, Claudia Coassin, Stefan Forer, Lukas Würzner, Reinhard Schönherr, Sebastian Kronenberg, Florian |
author_facet | Di Maio, Silvia Lamina, Claudia Coassin, Stefan Forer, Lukas Würzner, Reinhard Schönherr, Sebastian Kronenberg, Florian |
author_sort | Di Maio, Silvia |
collection | PubMed |
description | BACKGROUND: Comorbidities including ischemic heart disease (IHD) worsen outcomes after SARS‐CoV‐2 infections. High lipoprotein(a) [Lp(a)] concentrations are a strong risk factor for IHD and possibly for thromboembolic events. We therefore evaluated whether SARS‐CoV‐2 infections modify the risk of high Lp(a) concentrations for IHD or thromboembolic events during the first 8.5 months follow‐up of the pandemic. METHOD: Cohort study using data from the UK Biobank during the SARS‐CoV‐2 pandemic. Baseline Lp(a) was compared between SARS‐CoV‐2 positive patients and the population controls. RESULTS: SARS‐CoV‐2 positive patients had Lp(a) concentrations similar to the population controls. The risk for IHD increased with higher Lp(a) concentrations in both, the population controls (n = 435,104) and SARS‐CoV‐2 positive patients (n = 6937). The causality of the findings was supported by a genetic risk score for Lp(a). A SARS‐CoV‐2 infection modified the association with a steeper increase in risk for infected patients (interaction p‐value = 0.03). Although SARS‐CoV‐2 positive patients had a five‐times higher frequency of thromboembolic events compared to the population controls (1.53% vs. 0.31%), the risk was not influenced by Lp(a). CONCLUSIONS: SARS‐CoV‐2 infections enforce the association between high Lp(a) and IHD but the risk for thromboembolic events is not influenced by Lp(a). |
format | Online Article Text |
id | pubmed-8242884 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82428842021-07-01 Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events Di Maio, Silvia Lamina, Claudia Coassin, Stefan Forer, Lukas Würzner, Reinhard Schönherr, Sebastian Kronenberg, Florian J Intern Med Brief Reports BACKGROUND: Comorbidities including ischemic heart disease (IHD) worsen outcomes after SARS‐CoV‐2 infections. High lipoprotein(a) [Lp(a)] concentrations are a strong risk factor for IHD and possibly for thromboembolic events. We therefore evaluated whether SARS‐CoV‐2 infections modify the risk of high Lp(a) concentrations for IHD or thromboembolic events during the first 8.5 months follow‐up of the pandemic. METHOD: Cohort study using data from the UK Biobank during the SARS‐CoV‐2 pandemic. Baseline Lp(a) was compared between SARS‐CoV‐2 positive patients and the population controls. RESULTS: SARS‐CoV‐2 positive patients had Lp(a) concentrations similar to the population controls. The risk for IHD increased with higher Lp(a) concentrations in both, the population controls (n = 435,104) and SARS‐CoV‐2 positive patients (n = 6937). The causality of the findings was supported by a genetic risk score for Lp(a). A SARS‐CoV‐2 infection modified the association with a steeper increase in risk for infected patients (interaction p‐value = 0.03). Although SARS‐CoV‐2 positive patients had a five‐times higher frequency of thromboembolic events compared to the population controls (1.53% vs. 0.31%), the risk was not influenced by Lp(a). CONCLUSIONS: SARS‐CoV‐2 infections enforce the association between high Lp(a) and IHD but the risk for thromboembolic events is not influenced by Lp(a). John Wiley and Sons Inc. 2021-10-29 2022-01 /pmc/articles/PMC8242884/ /pubmed/34096654 http://dx.doi.org/10.1111/joim.13338 Text en © 2021 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Brief Reports Di Maio, Silvia Lamina, Claudia Coassin, Stefan Forer, Lukas Würzner, Reinhard Schönherr, Sebastian Kronenberg, Florian Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events |
title | Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events |
title_full | Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events |
title_fullStr | Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events |
title_full_unstemmed | Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events |
title_short | Lipoprotein(a) and SARS‐CoV‐2 infections: Susceptibility to infections, ischemic heart disease and thromboembolic events |
title_sort | lipoprotein(a) and sars‐cov‐2 infections: susceptibility to infections, ischemic heart disease and thromboembolic events |
topic | Brief Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242884/ https://www.ncbi.nlm.nih.gov/pubmed/34096654 http://dx.doi.org/10.1111/joim.13338 |
work_keys_str_mv | AT dimaiosilvia lipoproteinaandsarscov2infectionssusceptibilitytoinfectionsischemicheartdiseaseandthromboembolicevents AT laminaclaudia lipoproteinaandsarscov2infectionssusceptibilitytoinfectionsischemicheartdiseaseandthromboembolicevents AT coassinstefan lipoproteinaandsarscov2infectionssusceptibilitytoinfectionsischemicheartdiseaseandthromboembolicevents AT forerlukas lipoproteinaandsarscov2infectionssusceptibilitytoinfectionsischemicheartdiseaseandthromboembolicevents AT wurznerreinhard lipoproteinaandsarscov2infectionssusceptibilitytoinfectionsischemicheartdiseaseandthromboembolicevents AT schonherrsebastian lipoproteinaandsarscov2infectionssusceptibilitytoinfectionsischemicheartdiseaseandthromboembolicevents AT kronenbergflorian lipoproteinaandsarscov2infectionssusceptibilitytoinfectionsischemicheartdiseaseandthromboembolicevents |